Ceballos G, Nájera N, Meaney E, Ortiz-Flores M

Idioma: Inglés [English version]
Referencias bibliográficas: 5
Paginas: s179-181
Archivo PDF: 225.76 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000.

2. Nordestgaard BG, Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2013; 118: 547-563.

3. Contois JH, McConnel JP, Sethi AA et al. Apolipoprotein B and cardiovascular disease risk: position statement from the aacc lipoproteins and vascular diseases division working group on best practices. Clin Chem. 2009; 55: 407-419.

4. Cole TG, Contois JH, Csako G et al. Association of apolipoprotein B and Nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2013; 2013: 752-770.

5. Johnson C. Diffusion ordered nuclear magnetic resonance spectroscopy: principles and applications. Prog Nucl Magn Reson Spectrosc. 1999; 34: 203-256.